Singapore-based AI healthtech Holmusk raises $45M Series C for its mental health data platform serving APAC health systems. The round expands Holmusk's real-world evidence and AI-driven mental health analytics to Japan, South Korea, and Australia.
## Holmusk $45M Series C: AI for the APAC Mental Health Treatment Gap
Holmusk, a Singapore-headquartered digital health company, has raised $45M in a Series C funding round to expand its AI-powered mental health data platform across APAC. The round represents one of the largest healthtech raises in Singapore in 2026 and signals growing investor confidence in APAC-origin healthcare AI companies.
### What Holmusk Does
Holmusk operates at the intersection of mental health care delivery and data science. The company's flagship product is NeuroBlu — a real-world evidence (RWE) platform that aggregates de-identified psychiatric patient data from health systems and uses AI and statistical analysis to generate insights for:
- **Pharmaceutical companies**: identifying patient populations for clinical trials, understanding treatment patterns and outcomes, and generating regulatory-grade real-world evidence - **Health systems**: understanding population-level mental health trends, optimising care pathways, and benchmarking outcomes against comparable populations - **Researchers**: accessing structured real-world mental health data for epidemiological and health economics research
### The APAC Mental Health Opportunity
The APAC mental health market has several characteristics that make Holmusk's data platform particularly relevant:
**Treatment gap**: Across APAC, the proportion of people with mental health conditions who receive treatment ranges from 5% (Indonesia, Vietnam) to 30% (Australia, Singapore). Data-driven insights are needed to understand and close this gap.
**Underdeveloped data infrastructure**: Mental health data in APAC is highly fragmented and inconsistently structured. Countries like Japan and Korea have significant psychiatric care capacity but minimal data standardisation — creating an opportunity for platforms that can aggregate and harmonise this data.
**Regulatory tailwinds**: Singapore, Australia, and Japan are developing national mental health data strategies that create demand for data platforms that can support population-level analysis.
### AIMenta Assessment
Holmusk represents the emerging category of APAC-origin, domain-specific AI companies that are building durable competitive positions by combining deep local market knowledge with AI-native data products. The mental health domain is particularly attractive because data is genuinely scarce, domain expertise is critical, and regulatory requirements create a moat against generalist AI competitors.
For APAC health systems and policymakers interested in mental health analytics: Holmusk's NeuroBlu platform is worth evaluating for population-level mental health strategy and outcome benchmarking.
How AIMenta helps clients act on this
Where this story lands in our practice — explore the relevant service line and market.
Beyond this story
Cross-reference our practice depth.
News pieces sit on top of working capability. Browse the service pillars, industry verticals, and Asian markets where AIMenta turns these stories into engagements.
Other service pillars
By industry
Other Asian markets
Related stories
-
Funding ·
Turing Raises USD 120M Series C from ENEOS, Isuzu, and SoftBank Vision Fund 2 for Japanese Autonomous Fleet AI
Tokyo-based Turing, building autonomous driving AI for Japanese logistics and commercial fleets, raises USD 120 million Series C from ENEOS, Isuzu, and SoftBank Vision Fund 2 — the largest Japanese autonomous vehicle AI funding round of 2026.
-
Funding ·
Scale AI Expands APAC Data Labelling Operations to Address Southeast Asian LLM Data Gap
Scale AI expanding APAC data labelling operations addresses the primary constraint on APAC LLM quality — APAC language data scarcity explains why Indonesian, Thai, Vietnamese, and Filipino model performance lags English; high-quality APAC labelled data is the limiting factor.
-
Funding ·
Singapore AI Startup Imbue Raises $200M Series B for Autonomous Enterprise Agent Platform
Singapore AI startup Imbue raises $200M Series B to build autonomous AI agents for APAC enterprise workflows — targeting insurance claims processing, financial compliance automation, and supply chain decision-making in Singapore and Southeast Asian markets.
-
Research ·
NUS and MIT Research Shows APAC-Language LLMs Outperform English-First Models on Legal and Financial Reasoning
NUS and MIT publish multilingual LLM reasoning research showing APAC-language models trained on Mandarin and Japanese outperform English-first models on APAC legal and financial benchmarks by 18-31 percentage points.
-
APAC ·
MAS Singapore Launches GenAI Regulatory Sandbox for APAC Financial Institutions
Singapore MAS launches GenAI sandbox for APAC financial institutions to test large language models in a regulatory environment. Gives APAC fintechs supervised access to trial GenAI in credit decisioning, fraud detection, and customer advisory without full regulatory approval.